semaj83/ctmatch_classification huggingface dataset:
Patient description: The patient is a 25-year-old man with type 1 diabetes confirmed with molecular analysis 7 years ago. He presents to the clinic with shortness of breath and fatigue during activities. He claims mild dyspnea after climbing 3 floors, no dyspnea at rest and no angina (New York Heart Association class 2). He is diagnosed with cardiomyopathy that will be treated with ACE inhibitors and Beta blockers. His takes 70/30 Insulin and vitamin D supplements. His past medical history is not significant for any other medical issues. His family history is positive for DM type 1 in his uncle and his grandfather. His lab study is as bellow: FBS: 100 mg/dl HbA1c: 6.5% Cholesterol: 190 mg/dl TG: 140 mg/dl LDL: 125 mg/dl HDL: 40 mg/dl

Clinical trial eligibility criteria: eligible ages (years): 35.0-75.0,  Hyperlipidemia Diabetes Mellitus, Type 2 Non-Insulin Dependent Diabetes Mellitus Male and female subjects with a diagnosis of type 2 diabetes mellitus who either have never had a major adverse cardiac event (MACE) diagnosed before or who had a MACE diagnosed at least 6 months ago, but who, according to the judgement of the treating general practitioner, do not receive any hyperlipidemic therapy. Major adverse cardiac events (MACE) myocardial infarction, coronary angioplasty, coronary artery bypass graft or other revascularization procedures. At Screening: Visit 1 (week -4): 1. Male patients aged >35 and ≤75 years and postmenopausal female patients ≤75 years with a diagnosis of type 2 diabetes mellitus 2. Patients have been euthyroid for at least six months 3. Written informed consent obtained At Visit 2 (week 0): 4. LDL cholesterol ≥130 mg/dl (3.3 mmol/l ) and <190 mg/dl (4.9 mmol/l) 5. Triglycerides <150 mg/dl (1.69 mmol/l ) and <600 mg/dl (11.3 mmol/l) 6. Sum of LDL-5 and LDL-6 cholesterol ≥25 mg/dl (0.65 mmol/l) 7. Follicle stimulating Hormone (FSH) >30 U/l in female patients aged <60 years or FSH >20 U/l in female patients aged ≥60 years  HbA1c > 8.0 Creatine kinase (CK) >5 times the upper limit of normal Patients having taken lipid lowering medication within 8 weeks of the screening visit
Patient description: The patient is a 25-year-old man with type 1 diabetes confirmed with molecular analysis 7 years ago. He presents to the clinic with shortness of breath and fatigue during activities. He claims mild dyspnea after climbing 3 floors, no dyspnea at rest and no angina (New York Heart Association class 2). He is diagnosed with cardiomyopathy that will be treated with ACE inhibitors and Beta blockers. His takes 70/30 Insulin and vitamin D supplements. His past medical history is not significant for any other medical issues. His family history is positive for DM type 1 in his uncle and his grandfather. His lab study is as bellow: FBS: 100 mg/dl HbA1c: 6.5% Cholesterol: 190 mg/dl TG: 140 mg/dl LDL: 125 mg/dl HDL: 40 mg/dl

Clinical trial eligibility criteria: eligible ages (years): 30.0-67.0,  Type 2 Diabetes Cardiovascular Disease Age 30 to 67 years at visit. 2. Diagnosed with T2DM at least 6 months prior to enrollment, under the active care of a doctor for at least the six months prior to enrollment, and HbA1c ≥ 8.0 %. 3. Body Mass Index (BMI) ≥ 30.0 kg/m2 and ≤ 39.9 kg/m2 at visit. 4. Willingness to accept random assignment to either treatment group. 5. Expect to live or work within approximately one hour's traveling time from the study clinic for the duration of the two-year trial. 6. Willingness to comply with the follow-up protocol and successful completion of the run-in (described below). 7. Written informed consent  Cardiovascular event (myocardial infarction, acute coronary syndrome, coronary artery angioplasty or bypass, stroke) in the past six months. 2. Current evidence of congestive heart failure, angina pectoris, or symptomatic peripheral vascular disease. 3. Cardiac stress test indicating that surgery or IMM would not be safe. 4. Pulmonary embolus or thrombophlebitis in the past six months. 5. Cancer of any kind (except basal cell skin cancer or cancer in situ) unless documented to be disease-free for five years. 6. Significant anemia (hemoglobin 1.0 g or more below normal range) or history of coagulopathy. 7. Serum creatinine ≥ 1.5 mg/dl. 8. HbA1c > 14.0%
Patient description: The patient is a 25-year-old man with type 1 diabetes confirmed with molecular analysis 7 years ago. He presents to the clinic with shortness of breath and fatigue during activities. He claims mild dyspnea after climbing 3 floors, no dyspnea at rest and no angina (New York Heart Association class 2). He is diagnosed with cardiomyopathy that will be treated with ACE inhibitors and Beta blockers. His takes 70/30 Insulin and vitamin D supplements. His past medical history is not significant for any other medical issues. His family history is positive for DM type 1 in his uncle and his grandfather. His lab study is as bellow: FBS: 100 mg/dl HbA1c: 6.5% Cholesterol: 190 mg/dl TG: 140 mg/dl LDL: 125 mg/dl HDL: 40 mg/dl

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Dyslipidemia Subject has successfully completed the double-blind study (LCP-AtorFen-2001; NCT00504829). 2. Subject has confirmed his or her willingness to participate in this study after being informed of all aspects of the study by voluntarily signing and dating an informed consent form in accordance with Good Clinical Practice (GCP)  Study drug compliance <70% in the double-blind study. 2. Any ongoing serious adverse event, or any ongoing non-serious moderate or severe adverse event from the double-blind study that is rated as possibly, probably or definitely related to study drug. 3. Resting blood pressure >/=160 mm Hg systolic and/or >/=100 mm Hg diastolic. 4. Symptoms of unexplained muscle pain, tenderness or weakness (i.e., signs indicative of possible myopathy), or any diagnosis of myopathy or rhabdomyolysis. 5. Any clinically significant change in physical exam or electrocardiogram from Visit 2 to Visit 6 of the double-blind study. 6. Any clinically significant change from Visit 1 to Visit 6 of the double-blind study in medical history including, but not limited to: a diagnosis of insulin-dependent diabetes mellitus (DM); poorly controlled DM; poorly controlled hypertension; significant renal, pulmonary, hepatic, biliary, or gastrointestinal disease; cancer (except non-melanoma skin cancer); and epilepsy. 7. Unwilling to abstain from medications, supplements, ingredients and herbal therapies that were excluded in the double-blind study and continue to be excluded in the open-label study. 8. Women who are pregnant, planning to be pregnant during the study period, lactating, or women of childbearing potential (not surgically sterilized between menarche and menopause) who are not using a medically approved method of contraception. 9. Other conditions might apply
Patient description: The patient is a 25-year-old man with type 1 diabetes confirmed with molecular analysis 7 years ago. He presents to the clinic with shortness of breath and fatigue during activities. He claims mild dyspnea after climbing 3 floors, no dyspnea at rest and no angina (New York Heart Association class 2). He is diagnosed with cardiomyopathy that will be treated with ACE inhibitors and Beta blockers. His takes 70/30 Insulin and vitamin D supplements. His past medical history is not significant for any other medical issues. His family history is positive for DM type 1 in his uncle and his grandfather. His lab study is as bellow: FBS: 100 mg/dl HbA1c: 6.5% Cholesterol: 190 mg/dl TG: 140 mg/dl LDL: 125 mg/dl HDL: 40 mg/dl

Clinical trial eligibility criteria: eligible ages (years): 18.0-90.0,  Atherosclerosis Ischemic Heart Disease Usually for Abciximab, that is Adjunct to PCI for the prevention of cardiac ischemic complications In patients undergoing PCI In patients with UA not responding to conventional medical therapy when PCI is planned within 24 hours  Usually for Abciximab, that is Active internal bleeding, recent (within 6 weeks) gastrointestinal (GI) or genitourinary (GU) bleeding of clinical significance History of cerebrovascular accident (CVA) within 2 years, or CVA with a significant residual neurological deficit Bleeding diathesis Administration of oral anticoagulants within 7 days unless prothrombin time is less than or equal to 1.2 times control, thrombocytopenia (<100,000 cells/µL) Recent (within 6 weeks) major surgery or trauma Intracranial neoplasm Arteriovenous malformation, or aneurysm Severe uncontrolled hypertension
Patient description: The patient is a 25-year-old man with type 1 diabetes confirmed with molecular analysis 7 years ago. He presents to the clinic with shortness of breath and fatigue during activities. He claims mild dyspnea after climbing 3 floors, no dyspnea at rest and no angina (New York Heart Association class 2). He is diagnosed with cardiomyopathy that will be treated with ACE inhibitors and Beta blockers. His takes 70/30 Insulin and vitamin D supplements. His past medical history is not significant for any other medical issues. His family history is positive for DM type 1 in his uncle and his grandfather. His lab study is as bellow: FBS: 100 mg/dl HbA1c: 6.5% Cholesterol: 190 mg/dl TG: 140 mg/dl LDL: 125 mg/dl HDL: 40 mg/dl

Clinical trial eligibility criteria: eligible ages (years): 18.0-75.0,  Hypertriglyceridemia triglycerides ≥ 250 mg/dL and < 600 mg/dL BMI between 18.5 and 45 Signed informed consent form  Fasting glucose ≥ 126 mg/dL Glycosylated hemoglobin (HbA1c) > 6.5% LDL cholesterol > 190 mg/dL Known history of type I and II DM Known history of type I and III hyperlipidemia Weight change > 3 kg between screening and baseline visits Pregnancy or intention to become pregnant Presence of significant underlying conditions that may interfere with the assessments of the study drug
Patient description: The patient is a 25-year-old man with type 1 diabetes confirmed with molecular analysis 7 years ago. He presents to the clinic with shortness of breath and fatigue during activities. He claims mild dyspnea after climbing 3 floors, no dyspnea at rest and no angina (New York Heart Association class 2). He is diagnosed with cardiomyopathy that will be treated with ACE inhibitors and Beta blockers. His takes 70/30 Insulin and vitamin D supplements. His past medical history is not significant for any other medical issues. His family history is positive for DM type 1 in his uncle and his grandfather. His lab study is as bellow: FBS: 100 mg/dl HbA1c: 6.5% Cholesterol: 190 mg/dl TG: 140 mg/dl LDL: 125 mg/dl HDL: 40 mg/dl

Clinical trial eligibility criteria: eligible ages (years): 0.0-999.0,  Dilated Cardiomyopathy Hypertrophic Cardiomyopathy Mitochondrial Cardiomyopathy Noncompaction Cardiomyopathy Restrictive Cardiomyopathy Individuals with a diagnosis of cardiomyopathy Family members of individuals with a diagnosis of cardiomyopathy Individuals with a nuclear mutation shown to confer risk of cardiomyopathy but who do not themselves have cardiomyopathy  Individuals who do not have cardiomyopathy, a relative with cardiomyopathy, or a nuclear mutation predisposing to cardiomyopathy
Patient description: The patient is a 25-year-old man with type 1 diabetes confirmed with molecular analysis 7 years ago. He presents to the clinic with shortness of breath and fatigue during activities. He claims mild dyspnea after climbing 3 floors, no dyspnea at rest and no angina (New York Heart Association class 2). He is diagnosed with cardiomyopathy that will be treated with ACE inhibitors and Beta blockers. His takes 70/30 Insulin and vitamin D supplements. His past medical history is not significant for any other medical issues. His family history is positive for DM type 1 in his uncle and his grandfather. His lab study is as bellow: FBS: 100 mg/dl HbA1c: 6.5% Cholesterol: 190 mg/dl TG: 140 mg/dl LDL: 125 mg/dl HDL: 40 mg/dl

Clinical trial eligibility criteria: eligible ages (years): 18.0-45.0,  Type 1 Diabetes Male Type 1 diabetes duration between zero and fifteen years current insulin therapy  Female proliferative retinopathy microalbuminuria symptomatic diabetic neuropathy cardiovascular disease taking medications smoking
Patient description: The patient is a 25-year-old man with type 1 diabetes confirmed with molecular analysis 7 years ago. He presents to the clinic with shortness of breath and fatigue during activities. He claims mild dyspnea after climbing 3 floors, no dyspnea at rest and no angina (New York Heart Association class 2). He is diagnosed with cardiomyopathy that will be treated with ACE inhibitors and Beta blockers. His takes 70/30 Insulin and vitamin D supplements. His past medical history is not significant for any other medical issues. His family history is positive for DM type 1 in his uncle and his grandfather. His lab study is as bellow: FBS: 100 mg/dl HbA1c: 6.5% Cholesterol: 190 mg/dl TG: 140 mg/dl LDL: 125 mg/dl HDL: 40 mg/dl

Clinical trial eligibility criteria: eligible ages (years): 18.0-70.0,  Diabetic Nephropathy The participant is male or female diagnosed with Type 2 Diabetes mellitus defined by the American Diabetes Association and must be aged 18 to 70 years. 2. The participant must have documented Advanced Diabetic Nephropathy (ADN) defined as presence of proteinuria or micro/macro-albuminuria and impaired GFR (by MDRD equation) corresponding to Chronic Kidney Disease (CKD) stages 3-4 (moderate-severe i.e. estimated GFR >15ml/min and <60ml/min). A. Presence of macroalbuminuria B. Presence of microalbuminuria if no therapy with ACE inhibitors or ARBs C. Presence of current microalbuminuria and previous documentation of macroalbuminuria D. Presence of current microalbuminuria and previous documentation of Diabetic Retinopathy or laser therapy E. If only microalbuminuria and no A, B, C or D US of kidney shows NL size. 3. Minimal cognitive function for a diabetes self management 4. Fasting or random Blood glucose <400mg/DL  Patients with Type 1 Diabetes Mellitus. 2. Serum Creatinine > 4.0 mg/dl and/or an estimated GFR of < 15 ml/min. 3. Patients on renal replacement therapy. 4. Patients with Hyperkalemia (K>5.0 meq/L). 5. Patients with known Renal Artery stenosis. 6. Patients with known cancer, hepatic impairment, dementia or other chronic medical diseases. 7. Patients with severe heart failure (NYHA Class III or IV symptoms and/or LVEF <25%). 8. Patients with valvular or outflow tract obstruction. 9. Patients with significant disability that precludes regular attendance at clinics for follow-up. 10. Patients unwilling or unable to provide informed consent. 11. Pregnant or lactating women. 12. Current addiction to substance or alcohol abuse
Patient description: The patient is a 25-year-old man with type 1 diabetes confirmed with molecular analysis 7 years ago. He presents to the clinic with shortness of breath and fatigue during activities. He claims mild dyspnea after climbing 3 floors, no dyspnea at rest and no angina (New York Heart Association class 2). He is diagnosed with cardiomyopathy that will be treated with ACE inhibitors and Beta blockers. His takes 70/30 Insulin and vitamin D supplements. His past medical history is not significant for any other medical issues. His family history is positive for DM type 1 in his uncle and his grandfather. His lab study is as bellow: FBS: 100 mg/dl HbA1c: 6.5% Cholesterol: 190 mg/dl TG: 140 mg/dl LDL: 125 mg/dl HDL: 40 mg/dl

Clinical trial eligibility criteria: eligible ages (years): 18.0-45.0,  Diabetes Healthy male or female subject 2. Age between 18 and 45 years (both inclusive) 3. Considered generally healthy upon completion of medical history, physical examination and biochemical investigations as judged by the Investigator. 4. Body Mass Index (BMI) between 18.0 and 35.0 kg/m2 (both inclusive) 5. Non-smoker, defined as no nicotine consumption for at least one year. 6. Signed and dated informed consent obtained before any trial-related activities  Previous participation in this trial or other clinical trials within the last 3 months. 2. Pregnant, breast-feeding or intention of becoming pregnant or not using adequate contraceptive measures. 3. Clinically significant abnormal hematology or biochemistry screening tests, as judged by the Investigator. 4. Any serious systemic infectious disease during the four weeks prior to the first dose of test drug, as judged by the Investigator. 5. History of any illness that, in the opinion of the Investigator, might confound the results of the trial or pose risk in administering the trial drug to the subject. In particular, subjects with significant cardiovascular disease, anemia (below the lower limit of normal) or hemoglobinopathy will not be allowed to enter the trial. 6. History of alcohol or drug abuse within the past 5 years and/or any positive test for drugs of abuse at screening. 7. Positive test for hepatitis B or C or HIV positive at screening or in the past. 8. Use of prescription drugs within 3 weeks preceding the first dosing of insulin, except for oral contraceptives/hormonal implants. 9. Use of any insulin product in the past. 10. Use of non-prescription drugs, except routine vitamins, within 2 weeks prior to the first dose of the test drug. Occasional use of acetaminophen will be permitted. 11. Blood donation of more than 500 mL (or considerable blood loss) within the last 12 weeks. 12. History of multiple and/or severe allergies to drugs or foods or a history of severe anaphylactic reaction. 13. Known or suspected allergy to trial products or related products. 14. Mental incapacity, unwillingness or language barriers precluding adequate understanding or co-operation
Patient description: The patient is a 25-year-old man with type 1 diabetes confirmed with molecular analysis 7 years ago. He presents to the clinic with shortness of breath and fatigue during activities. He claims mild dyspnea after climbing 3 floors, no dyspnea at rest and no angina (New York Heart Association class 2). He is diagnosed with cardiomyopathy that will be treated with ACE inhibitors and Beta blockers. His takes 70/30 Insulin and vitamin D supplements. His past medical history is not significant for any other medical issues. His family history is positive for DM type 1 in his uncle and his grandfather. His lab study is as bellow: FBS: 100 mg/dl HbA1c: 6.5% Cholesterol: 190 mg/dl TG: 140 mg/dl LDL: 125 mg/dl HDL: 40 mg/dl

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Diabetes Mellitus Atherosclerosis The study will 40 patients aged 18 years or older with DM, defined as patients with fasting plasma glucose above 126 mg/dL or symptoms of DM with random blood glucose concentration of above 200 mg/dL, or patients treated with oral hypoglycemics or insulin In addition, prior to their enrollment in the study patients' BP will be assessed by 24 hour ambulatory BP monitoring All patients will have to be treated with ACE inhibitors, aspirin and statins for at least one month prior to their enrollment in the study Patients' medication regimen will not be altered during the study period Patients will sign a written informed consent before their in the study  Patients will be excluded from the study if their systolic BP is between bellow 110 mmHg or above 150 mmHg mmHg Major will be acute coronary syndrome in the 6 months previous to the study renal failure with creatinin levels above 1.5 mg/dL hyperkalemia (K > 5 mg/dL) hematologic or solid malignancies pregnancy a platelet count below 100,000
Patient description: The patient is a 25-year-old man with type 1 diabetes confirmed with molecular analysis 7 years ago. He presents to the clinic with shortness of breath and fatigue during activities. He claims mild dyspnea after climbing 3 floors, no dyspnea at rest and no angina (New York Heart Association class 2). He is diagnosed with cardiomyopathy that will be treated with ACE inhibitors and Beta blockers. His takes 70/30 Insulin and vitamin D supplements. His past medical history is not significant for any other medical issues. His family history is positive for DM type 1 in his uncle and his grandfather. His lab study is as bellow: FBS: 100 mg/dl HbA1c: 6.5% Cholesterol: 190 mg/dl TG: 140 mg/dl LDL: 125 mg/dl HDL: 40 mg/dl

Clinical trial eligibility criteria: eligible ages (years): 18.0-75.0,  Type 2 Diabetes Individuals more than 18 years of age with DM2, either with new onset DM2 or known diabetics who did not take oral hypoglycemic agents for more than 2 weeks, presenting with fasting blood glucose (FBG) 300-500 mg/dl or random blood glucose (RBG) 400-700 mg/dl and who did not have any  listed in Table 1, were eligible for the study Acute metabolic complications (diabetic ketoacidosis, hyperosmolar hyperglycemia associated with dehydration) Acute complications of chronic cardiovascular, neurological, renal, and other diabetic complications Any subject with unstable vitals signs (temperature > 101 degrees F, systolic blood pressure < 90 or > 180 mm hg, diastolic blood pressure < 60 or > 110 mm hg, heart rate < 60 or > 120 beats/minute) Electrolyte imbalances (serum bicarbonate level < 20 mEq/L, serum sodium < 125 & > 150 mEq/L, serum potassium < 3.5 & > 5.5 mEq/L) Evidence of an impaired sensorium and/or dementia Age > 75 years Subjects with any acute medical illness Type 1 diabetes or type 2 diabetics weighing less than 120 lbs Current addiction to illicit substances or alcohol abuse
Patient description: The patient is a 25-year-old man with type 1 diabetes confirmed with molecular analysis 7 years ago. He presents to the clinic with shortness of breath and fatigue during activities. He claims mild dyspnea after climbing 3 floors, no dyspnea at rest and no angina (New York Heart Association class 2). He is diagnosed with cardiomyopathy that will be treated with ACE inhibitors and Beta blockers. His takes 70/30 Insulin and vitamin D supplements. His past medical history is not significant for any other medical issues. His family history is positive for DM type 1 in his uncle and his grandfather. His lab study is as bellow: FBS: 100 mg/dl HbA1c: 6.5% Cholesterol: 190 mg/dl TG: 140 mg/dl LDL: 125 mg/dl HDL: 40 mg/dl

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Multiple Myeloma and Plasma Cell Neoplasm Diagnosis of multiple myeloma based on the following Major Plasmacytomas on tissue biopsy (1) Bone marrow plasmacytosis (> 30% plasma cells) (2) Monoclonal immunoglobulin spike on serum electrophoresis IgG > 3.5 g/dL or IgA > 2.0 g/dL and kappa or lambda light chain excretion > 1 g/day on 24-hour urine protein electrophoresis (3) Minor Bone marrow plasmacytosis (10% to 30% plasma cells) (a) Monoclonal immunoglobulin present but of lesser magnitude than given under major (b) Lytic bone lesions (c) Normal IgM < 50 mg/dL, IgA < 100 mg/dL, or IgG < 600 mg/dL (d)